First author | Journal | Study design | VOC c | Vaccine | Country | Population characteristics | N |
---|---|---|---|---|---|---|---|
Shinde (2021) [20] | N Engl J Med | RCT | Beta (GS) | NVX-CoV2373 | South Africa | GP; age: 18–84 | 4,387 |
Madhi (2021) [22] | N Engl J Med | RCT | Beta (GS) | ChAdOx1 | South Africa | GP; age: 18–65 | 1,467 |
Heath (2021) [38] | N Engl J Med | RCT | Alpha (GS) | NVX-CoV2373 | UK | GP; age: 18–84 | 14,039 |
Sadoff (2022) [40] | N Engl J Med | RCT | Beta (GS) | Ad26.COV2.S | South Africa | GP; age: ≥18 | 4,969 |
Emary (2021) [23] | Lancet | RCT | Alpha (GS) | ChAdOx1 | UK | GP; age: ≥18 | 8,534 |
Ella (2021) [37] | Lancet | RCT | Delta (GS) | BBV152 | India | GP; age: 18–98 | 16,973 |
Thomas (2021) [41] | N Engl J Med | RCT | Beta (GS) | BNT162b2 | South Africa | GP; age: ≥16 | 800 |
Clemens (2021) [35] | Nat Commun | RCT | Gamma (GS) | ChAdOx1 | Brazil | GP; age: ≥18 | 10,416 |
Bravo (2022) [34] | Lancet | RCT | Gamma & Delta (GS) | SCB-2019 | Five regions | GP; age: ≥18 | 30,174 |
Dunkle (2022) [36] | N Engl J Med | RCT | Alpha (GS) | NVX-CoV2373 | USA and Mexico | GP; age: ≥18 | 29,949 |
Kremsner (2022) [39] | Lancet Infect Dis | RCT | Alpha & Gamma (GS) | CVnCoV | Europe/Latin America | GP; age: ≥18 | 39,680 |
Lopez Bernal_1 (2021) [21] | N Engl J Med | TNCC | Alpha & Delta (GS) | BNT162b2 or ChAdOx1 | UK | GP; age: ≥16 | 19,109 b |
Abu-Raddad (2021) [60] | N Engl J Med | TNCC | Alpha & Beta (GS) | BNT162b2 | Qatar | GP; age: 33 (22–40) a | 35,979 b |
Sheikh (2021) [80] | Lancet | TNCC | Alpha & Delta (GS) | BNT162b2 or ChAdOx1 | UK | GP; age: ≥16 | 19,543 b |
Chemaitelly_1 (2021) [67] | Nat Med | TNCC | Alpha & Beta (GS) | mRNA-1273 | Qatar | GP; age: 32 (25–39) a | 66,042 b |
Lopez Bernal_2 (2021) [76] | BMJ | TNCC | Alpha | BNT162b2 | UK | Older adults; age: ≥70 | 3,034 b |
Chung (2021) [68] | BMJ | TNCC | Alpha & Beta/Gamma (GS) | BNT162b2 and mRNA-1273 | Canada | GP; ≥16 | 324,033 b |
Ranzani (2021) [79] | BMJ | TNCC | Gamma | CoronaVac | Brazil | Older adults; ≥70 | 43,774 b |
Carazo (2021) [64] | Clin Infect Dis | TNCC | Alpha | BNT162b2 and mRNA-1273 | Canada | HCWs; age: 18–74 | 901 b |
Li (2021) [75] | Emerg Microbes Infect | TNCC | Delta (GS) | CoronaVac and BBIBP-CorV | China | GP; age:18–59 | 74 b |
Charmet (2021) [65] | Lancet Reg Health Eur | Case-control | Alpha & Beta/Gamma | BNT162b2 and mRNA-1273 | France | GP; age: ≥20 | 33,863 b |
Nasreen (2022) [77] | Nat Microbiol | TNCC | Alpha & Beta & Gamma & Delta (GS) | BNT162b2, mRNA-1273, or ChAdOx1 | Canada | GP; age: ≥16 | 51,440 b |
Hitchings_1 (2021) [73] | Lancet Reg Health Am | TNCC | Gamma | CoronaVac | Brazil | HCWs; age: ≥18 | 418 b |
Tang (2021) [82] | Nat Med | TNCC | Alpha & Delta | BNT162b2 or mRNA-1273 | Qatar | GP; age: 27 (12–36) a | 2,934 b |
Chemaitelly_2 (2021) [66] | N Engl J Med | TNCC | Alpha & Beta & Delta (GS) | BNT162b2 | Qatar | GP; age: 31 (21–39) a | 113,830 b |
Grannis (2021) [70] | MMWR | TNCC | Delta | BNT162b2, mRNA-1273 or Ad26.COV2.S | USA | GP; age: ≥18 | 3,657 b |
Sritipsukho (2022) [81] | Emerg Microbes Infect | TNCC | Delta | CoronaVac and/or ChAdOx1 | Thailand | GP; age: ≥18 | 1,118 b |
Klein (2022) [74] | MMWR | TNCC | Delta & Omicron | BNT162b2 or mRNA-1273 | USA | GP; age: ≥18 | 3,860 b |
Oliveira (2022) [78] | JAMA Network Open | TNCC | Delta (GS) | BNT162b2 | USA | Adolescents; 12–18 | 186 b |
Tseng (2022) [84] | Nat Med | TNCC | Delta & Omicron (GS) | mRNA-1273 | USA | GP; age: ≥18 | 23,512 b |
Ferdinands (2022) [69] | MMWR | TNCC | Delta & Omicron | BNT162b2 or mRNA-1273 | USA | GP; age: ≥18 | 18, 637 b |
Britton (2022) [63] | JAMA | TNCC | Delta | BNT162b2, mRNA-1273, or Ad26.COV2.S. | USA | GP; age: ≥12 | 329,057 b |
Grant (2022) [71] | Lancet Reg Health Eur | Case-control | Delta | BNT162b2 or mRNA-1273 | France | GP; age: ≥20 | 8,644 b |
Andrews_1 (2022) [62] | N Engl J Med | TNCC | Delta | BNT162b2 or ChAdOx1 | UK | GP; age: ≥16 | 1,125,257 b |
Andrews_2 (2022) [61] | Nat Med | TNCC | Delta (GS) | BNT162b2 | UK | GP; age: ≥18 | 343,955 b |
Thiruvengadam (2021) [83] | Lancet Infect Dis | TNCC | Delta (GS) | ChAdOx1 | India | GP; age: 35 (28–45) a | 2,766 b |
Hitchings_2 (2021) [72] | Nat Commun | TNCC | Gamma | ChAdOx1 | Brazil | Older adults; ≥60 | 30,680 b |
Hall (2021) [6] | Lancet | PRO cohort | Alpha | BNT162b2 | UK | HCWs; age: ≥18 | 23,324 |
Haas (2021) [46] | Lancet | RETRO cohort | Alpha | BNT162b2 | Israel | GP; age: ≥16 | 6,538,911 |
Dagan (2021) [7] | N Engl J Med | RETRO cohort | Alpha | BNT162b2 | Israel | GP; age: ≥16 | 1,193,236 |
Lumley (2021) [49] | Clin Infect Dis | RETRO cohort | Alpha (GS) | BNT162b2 and ChAdOx1 | UK | HCWs; age: 39(30–50) a | 13,109 |
Williams (2021) [58] | Clin Infect Dis | RETRO cohort | Gamma (GS) | mRNA-1273 | Canada | LTCH | 143 |
Nanduri (2021) [51] | MMWR | RETRO cohort | Delta | mRNA-1273 or BNT162b2 | US | Nursing home | 5,965,607 |
Fowlkes (2021) [44] | MMWR | RETRO cohort | Delta | mRNA-1273 and BNT162b2 | US | Frontline workers | 2,840 |
Pouwels (2021) [53] | Nat Med | RETRO cohort | Alpha & Delta | BNT162b2 or ChAdOx1 or mRNA-1273 | UK | GP; age: 18–64 | 743,526 |
Flacco (2021) [43] | Vaccines | RETRO cohort | Alpha | BNT162b2 | Italian | GP; age: ≥18 | 204,840 |
Glatman-Freedman (2021) [45] | Emerg Infect Dis | RETRO cohort | Delta | BNT162b2 | Israel | Adolescents; 12–15 | 601,625 |
Seppälä (2021) [56] | Euro Surveill | RETRO cohort | Alpha & Delta (GS) | BNT162b2 or mRNA-1273 | Norway | GP; age: ≥18 | 18,431 |
Fabiani (2022) [42] | BMJ | RETRO cohort | Alpha & Delta | BNT162b2 or mRNA-1273 | Italy | GP; age: ≥16 | 33,250,344 |
Risk (2022) [55] | Clin Infect Dis | RETRO cohort | Delta | BNT162b2, mRNA-1273, or Ad26.COV2.S. | USA | GP; age: ≥18 | 159,055 |
Kang (2022) [47] | Ann Intern Med | RETRO cohort | Delta (GS) | CoronaVac or HB02 | China | GP; age: ≥18 | 10,805 |
Poukka (2022) [52] | Vaccine | RETRO cohort | Delta | BNT162b2 or mRNA-1273 or ChAdOx1 | Finland | 16–69 HCWs | 427,905 |
Wu (2022) [59] | China CDC Wkly | RETRO cohort | Delta (GS) | BBIBP-CorV or CoronaVac | China | Close contacts; age: ≥18 | 1,462 |
Katz (2022) [48] | Vaccine | PRO cohort | Alpha (GS) | BNT162b2 | Israel | HCWs; age: 45 (36–55) a | 1,250 |
Lutrick (2021) [50] | MMWR | PRO cohort | Delta | BNT162b2 | USA | Adolescents; 12–17 | 243 |
Reis (2021) [54] | N Engl J Med | RETRO cohort | Delta | BNT162b2 | Israel | Adolescents; 12–18 | 188,708 |
Tartof (2021) [57] | Lancet | RETRO cohort | Delta (GS) | mRNA-1273 | USA | GP; age: ≥12 | 3,436,957 |